Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support

被引:96
作者
Grebely, Jason [1 ]
Knight, Elizabeth [2 ]
Genoway, Krista A. [2 ]
Viljoen, Mark [3 ]
Khara, Milan [3 ]
Elliott, Doug [3 ]
Gallagher, Lesley [2 ]
Storms, Michelle [2 ]
Raffa, Jesse D. [4 ]
DeVlaming, Stanley [3 ]
Duncan, Fiona [3 ]
Conway, Brian [2 ,3 ]
机构
[1] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia
[2] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada
[3] Vancouver Coastal Hlth, Pender Community Hlth Ctr, Vancouver, BC, Canada
[4] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada
基金
加拿大健康研究院;
关键词
assessment; hepatitis C virus; illicit drug users; injection drug users; treatment; DIRECTLY OBSERVED THERAPY; INTERFERON-ALPHA; METHADONE-MAINTENANCE; ANTIVIRAL TREATMENT; PLUS RIBAVIRIN; HCV INFECTION; HIV; BARRIERS; REINFECTION; AUSTRALIA;
D O I
10.1097/MEG.0b013e32832a8c4c
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives We evaluated assessment and treatment for hepatitis C virus (HCV) among illicit drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary community health centre. Methods From March 2005 to 2008, HCV-infected individuals were referred to a weekly peer-support group and assessed for HCV infection. A retrospective chart review of outcomes 3 years after the initiation of the group was conducted (including HCV assessment and treatment). Results Two hundred and four HCV antibody-positive illicit drug users accepted referral to a weekly HCV peer-support group. Assessment for HCV occurred in 53% of patients (n = 109), with 13% (n = 14) having initiated or completed treatment for HCV infection before attending the support group, evaluation ongoing in 10% (n = 11) and treatment deferred/not indicated in 25% (n = 27). The major reasons for HCV treatment deferral included early disease (30%), drug dependence (37%), other medical (11%) or psychiatric comorbidities (4%). Sixty-eight percent of those deferred for reasons other than early liver disease showed multiple reasons for treatment deferral. The first 4 weeks of support group attendance predicted successful HCV assessment (odds ratio: 6.03, 95% confidence interval: 3.27-11.12, P < 0.001). Overall, 28% (n = 57) received treatment. Among individuals having completed pegylated-interferon and ribavirin therapy with appropriate follow-up (n = 19), the rate of sustained virologic response was 63% (12/19), despite illicit drug use in 53%. Conclusion A high proportion of illicit drug users accepting referral to a weekly HCV peer-support group at a multidisciplinary health centre were assessed and treated for HCV infection. Peer support coupled with multidisciplinary care is an effective strategy for engaging illicit drug users in HCV care. Eur J Gastroenterol Hepatol 22: 270-277 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:270 / 277
页数:8
相关论文
共 40 条
[31]   Hepatitis C treatment in "Difficult-to-Treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects [J].
Schaefer, Martin ;
Hinzpeter, Axel ;
Mohmand, Ariane ;
Janssen, Gesa ;
Pich, Maurice ;
Schwaiger, Markus ;
Sarkar, Rahul ;
Friebe, Astrid ;
Heinz, Andreas ;
Kluschke, Michael ;
Ziemer, Marlene ;
Gutsche, Juri ;
Weich, Viola ;
Halangk, Juliane ;
Berg, Thomas .
HEPATOLOGY, 2007, 46 (04) :991-998
[32]   Natural history of chronic hepatitis C [J].
Seeff, LB .
HEPATOLOGY, 2002, 36 (05) :S35-S46
[33]   Global epidemiology of hepatitis C virus infection [J].
Shepard, CW ;
Finelli, L ;
Alter, M .
LANCET INFECTIOUS DISEASES, 2005, 5 (09) :558-567
[34]   Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users [J].
Strathdee, SA ;
Latka, M ;
Campbell, J ;
O'Driscoll, PT ;
Golub, ET ;
Kapadia, F ;
Pollini, RA ;
Garfein, RS ;
Thomas, DL ;
Hagan, H .
CLINICAL INFECTIOUS DISEASES, 2005, 40 :S304-S312
[35]   Integrating HCV services for drug users: A model to improve engagement and outcomes [J].
Sylvestre, Diana L. ;
Zweben, Joan E. .
INTERNATIONAL JOURNAL OF DRUG POLICY, 2007, 18 (05) :406-410
[36]   Treating hepatitis C in methadone maintenance patients: an interim analysis [J].
Sylvestre, DL .
DRUG AND ALCOHOL DEPENDENCE, 2002, 67 (02) :117-123
[37]   The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone [J].
Sylvestre, DL ;
Litwin, AH ;
Clements, BJ ;
Gourevitch, MN .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2005, 29 (03) :159-165
[38]   Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings [J].
Treloar, Carla ;
Holt, Martin .
AUSTRALIAN HEALTH REVIEW, 2008, 32 (03) :570-576
[39]  
Van Thiel DH, 2003, AM J GASTROENTEROL, V98, P2281, DOI 10.1111/j.1572-0241.2003.07702.x
[40]  
VanThiel DH, 1995, HEPATO-GASTROENTEROL, V42, P900